MCM
BLUE

Moore Capital Management’s bluebird bio BLUE Stock Holding History

Moore Capital Management’s Portfolio BLUE Stock Details BLUE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-772
Closed -$540K – 527
2020
Q3 		$540K Hold
772
– – 0.01% 317
2020
Q2 		$610K Buy
+772
New +$582K 0.02% 221
2018
Q1 		– Sell
-1,420
Closed -$3.28M – 255
2017
Q4 		$3.28M Buy
+1,420
New +$2.88M 0.06% 167

Other funds holding BLUE

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return

Moore Capital Management's BLUE Position: Q4 2020 in Review

Moore Capital Management sold out of bluebird bio (BLUE) in Q4 2020, closing a stake of 772 shares — an estimated $540K sold.

Moore Capital Management first reported a position in BLUE in Q4 2017 and held it in 3 quarters. The position peaked at $3.28M in Q4 2017. 262 funds tracked by Wall St. Rank hold BLUE as of Q4 2020.

  • Moore Capital Management reported no remaining bluebird bio position as of Q4 2020 after selling out during the quarter.
  • Moore Capital Management sold 772 bluebird bio shares in Q4 2020, an estimated $540K.
  • Moore Capital Management first reported a position in bluebird bio in Q4 2017 and held it in 3 quarters.
  • Moore Capital Management's bluebird bio position peaked at $3.28M in Q4 2017.
  • 262 funds tracked by Wall St. Rank held bluebird bio as of Q4 2020.

Based on Moore Capital Management's 13F filing for Q4 2020, filed 16 Feb 2021.